Trulieve Caught Between Insider Sales and Hopes for Cannabis Rescheduling
Veröffentlicht: 29.06.2026 um 17:25 Uhr, Redaktion boerse-global.de
Trulieve’s stock kicked off the week with a 7.1% surge to €8.15, fueled by the start of a high-stakes DEA hearing on cannabis rescheduling. Yet the rally unfolded against a backdrop of heavy insider selling: Chief Executive Kim Rivers offloaded 1.7 million shares in the days leading up to the hearing, collecting proceeds of roughly $1.2 million on the final transaction alone.
The largest single sale came on June 26, when Rivers sold nearly 137,000 shares at an average price of $8.76. All transactions took place between June 17 and June 26 under a pre-arranged trading plan compliant with Rule 10b5-1, which shields executives from insider-trading accusations. After the sales, Rivers still holds approximately 1.48 million shares directly.
The divergence between insider activity and market momentum highlights a complex picture. Trulieve’s stock has climbed 157% year-to-date, outpacing the broader cannabis sector. The annualized volatility over the past 30 days stands at 102%, and at €8.15 the shares trade 26% above the 200-day moving average of €6.47. Still, the price remains 29% below the 52-week high of €11.48 reached on June 9.
Regulatory tailwinds meet procedural controversy
The immediate catalyst for the latest leg higher is a formal DEA hearing that began June 29 in Arlington, Virginia, and is scheduled to run through July 15. At issue is whether cannabis should be moved from the restrictive Schedule I to the less stringent Schedule III. The Trump administration already took a step in that direction in April, placing FDA-approved and state-licensed medical-marijuana products into Schedule III. A broader reclassification would represent a seismic shift for the industry.
Should investors sell immediately? Or is it worth buying Trulieve?
Political support appears solid. Lawmakers from both parties have indicated they will not block the move, despite some earlier committee-level opposition. Yet the hearing itself has drawn criticism: reports show the DEA is only permitting witnesses who oppose reclassification, excluding reform advocates. That has raised questions about the transparency of the process and could inject uncertainty into the outcome.
Solid fundamentals beneath the headline swings
The recent insider sales come at a time of improving financial performance. In its most recent quarter, Trulieve reported $287 million in revenue, $2 million in net income, and adjusted EBITDA of $100 million. Free cash flow reached $42 million, and the company held $353 million in cash. The relative strength index sits at 44.8, suggesting neutral to slightly oversold territory.
The company’s operational footprint is expanding. In its home state of Florida, as well as in the newer markets of Georgia and Texas, Trulieve has been adding retail locations. The NYSE listing in early June provided additional credibility and access to institutional capital.
Trulieve at a turning point? This analysis reveals what investors need to know now.
For now, the stock is being pulled in two directions: the CEO’s share sales weigh on sentiment, while the regulatory calendar offers a potential catalyst. The next quarterly results will test whether the operational momentum can sustain the rally amid the insider signals.
Ad
Trulieve Stock: New Analysis - 29 June
Fresh Trulieve information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
